Rhythm Pharmaceuticals, Inc.
RYTM
A
|
$37.975
-0.35%
-0.36%
620K
|
Health Technology
(0.0% 1d) (-6.5% 1m) (82.7% 1y) (-0.3% 2d) (-1.1% 3d) (-5.2% 7d) (40.3% volume)
Earnings Calendar: 2024-02-22
Market Cap: $ 2,283,835,298
http://www.rhythmtx.com
Sec Filling | Patents | 70 employees
(US) Rhythm Pharmaceuticals, Inc. engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. It focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. Its product candidate includes setmelanotide, an MC4R agonist designed to restore impaired MC4R pathway function caused by genetic variants that occur upstream of the MC4R. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.
gastrointestinal car-t genetic mc4r agonist treatment
add to watch list Paper trade email alert is off
Press-releases
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Published: 2024-04-16 (Crawled : 20:00) - globenewswire.com
RYTM A | $37.975 -0.35% -0.36% 620K
|
Health Technology
|
| O: 1.51%
H: 0.0%
C: -1.66%
pharmaceuticals grants
Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing
Published: 2024-04-01 (Crawled : 12:00) - globenewswire.com
RYTM A | $37.975 -0.35% -0.36% 620K
|
Health Technology
|
| O: -0.02%
H: 1.11%
C: 0.9%
million pharmaceuticals
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist
Published: 2024-03-25 (Crawled : 12:00) - globenewswire.com
RYTM A | $37.975 -0.35% -0.36% 620K
|
Health Technology
|
| O: -0.37%
H: 1.71%
C: -1.86%
rm-718 first agonist pharmaceuticals trial
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Published: 2024-03-11 (Crawled : 20:00) - globenewswire.com
RYTM A | $37.975 -0.35% -0.36% 620K
|
Health Technology
|
| O: 0.57%
H: 2.87%
C: -1.37%
pharmaceuticals grants
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences
Published: 2024-03-06 (Crawled : 21:00) - globenewswire.com
RYTM A | $37.975 -0.35% -0.36% 620K
|
Health Technology
|
| O: 1.61%
H: 1.68%
C: -0.22%
pharmaceuticals
Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan
Published: 2024-02-22 (Crawled : 12:00) - globenewswire.com
RYTM A | $37.975 -0.35% -0.36% 620K
|
Health Technology
|
| O: 0.39%
H: 1.08%
C: -10.08%
obesity japan setmelanotide pharmaceuticals
Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update
Published: 2024-02-22 (Crawled : 12:00) - globenewswire.com
RYTM A | $37.975 -0.35% -0.36% 620K
|
Health Technology
|
| O: 0.39%
H: 1.08%
C: -10.08%
business update pharmaceuticals financial
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Published: 2024-02-08 (Crawled : 21:00) - globenewswire.com
RYTM A | $37.975 -0.35% -0.36% 620K
|
Health Technology
|
| O: 1.01%
H: 7.6%
C: 6.56%
pharmaceuticals grants
Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
Published: 2024-02-07 (Crawled : 13:00) - globenewswire.com
RYTM A | $37.975 -0.35% -0.36% 620K
|
Health Technology
|
| O: 0.25%
H: 2.05%
C: 0.06%
imcivree obesity control positive italy treatment pharmaceuticals
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
Published: 2024-01-31 (Crawled : 13:00) - globenewswire.com
RYTM A | $37.975 -0.35% -0.36% 620K
|
Health Technology
|
| O: 0.11%
H: 2.58%
C: -3.69%
report year pharmaceuticals financial results
Last 15 days Sec forms
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
Last 48 Hours Insiders Buying
RXO P 200000 | $19.37 2.32% 0.0% 1M
|
n/a
|
23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M
|
Finance
|
22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K
|
Health Technology
|
22:30
BCDA P 2750 | $0.377 -1.4% 97K
|
Health Technology
|
22:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10